One gene, multiple proteins
Our genome includes not more than 30,000 genes.
However, there are more than 150,000 different proteins in the human body.
How is this possible?
Almost every gene is composed of multiple "blocks" called exons.
The combination in which these exons are included or excluded from the final mRNA -the instruction to make a protein- allows the cells to produce different proteins from a single gene. Often, the same gene can be spliced differently to produce proteins with different -sometimes opposing- functions.
The revolutionary AON technology
In the past 20 years, Antisense Oligonucleotides (AONs), also know as ASOs or SSOs, have been used to modulate splicing, forcing the cells to use only certain exons for the production of specific proteins. AONs are safe, specific and widely used in clinic for multiple applications.
As of 2021, 7 different diseases can be treated with AONs, and there are more than 25 AONs in advanced clinical trials (phase II & III).
We modulate splicing of
Immunotherapy is growing, but needs some help.
At IMMUNOA, we believe that immunotherapy is the future for cancer treatment.
In the past 5 years we developed, optimized, and patented AONs that are modulating splicing (Splice-Switching Oligonucleotides, SSOs) of multiple genes involved in the immune response.
We do not limit ourselves to reduce the expression of genes that are making immunotherapy ineffective. We are converting these genes to their "good" isoform, through splicing.
A double-edged sword for cell-based immunotherapy.